Imunon, Inc. (IMNN) Dividend History

Company News

• IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules

  IMUNON, a clinical-stage biotechnology company, announced a $3.25 million private placement and the potential for an additional $6.5 million from the exercise of short-term warrants. The company plans to use the proceeds for working capital and general corporate purposes.

  GlobeNewswire Inc.
• IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer

  Novel IL-12 Immunotherapy Administered with Standard of Care as First-Line Treatment

  GlobeNewswire Inc.
• First Participants Vaccinated in IMUNON’s IMNN-101 Phase 1 Clinical Trial

  DNA vaccine proof-of-concept study expected to demonstrate an “mRNA better” platform

  GlobeNewswire Inc.
• Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting

  LAWRENCEVILLE, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that an abstract describing a Phase 2 study with IMNN-001 plus bevacizumab (Avastin®) and neoadjuvant chemotherapy in advanced epithelial ovarian cancer patients has been accepted for presentation at the American Society of Clinical Oncology (ASCO) annual meeting, to be held in Chicago from May 31st to June 4th.

  GlobeNewswire Inc.
• IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update

  Conference Call Begins Today at 11:00 a.m. Eastern Time

  GlobeNewswire Inc.